Xspray Pharma AB
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Xspray Pharma AB - overview
Established
2003
Location
-, -, Sweden
Primary Industry
Pharmaceuticals
About
Xspray Pharma AB is a Swedish biopharmaceutical company specializing in the development of innovative protein kinase inhibitors (PKIs) for cancer treatment, leveraging proprietary technology to enhance drug formulations. Founded in 2003 in Sweden, Xspray Pharma AB focuses on advancing cancer therapies through innovative drug formulations. The company has successfully raised SEK 100 million in a Private Placement/Follow on as of October 2022, utilizing the funds to enhance its market presence in the U. S.
and develop its product pipeline. The CEO, Per Andersson, leads the company in its mission to bring improved therapeutic options to market. Xspray Pharma specializes in developing pharmaceutical products, particularly its core offering, Dasynoc (dasatinib), an amorphous version of a marketed drug that aims to improve bioavailability. The company utilizes patented technology to create enhanced formulations of existing PKIs, allowing for market entry once related patents expire.
Targeting the U. S. market, Xspray Pharma aims to provide healthcare providers and patients with effective cancer treatment options. In 2021, Xspray Pharma reported zero revenue with an EBITDA of SEK -10,385,675.
2. The company primarily generates income through the commercialization of its pharmaceutical products, including Dasynoc, via direct sales to healthcare providers and partnerships with distributors, ensuring availability in pharmacies and hospitals. Following the SEK 100 million funding raised in October 2022, Xspray Pharma plans to enhance its marketing efforts in preparation for launching its product candidate XS003 in the American market. This funding will also support the development of its product portfolio, focusing on strengthening its presence in the U.
S. and accelerating the advancement of its growing pipeline of innovative PKI therapies.
Current Investors
Ribbskottet AB, VINNOVA, KDventures
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.xspray.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Xspray Pharma AB - timeline of key events
Xspray Pharma AB - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 1,797,398 | 1,831,206 | 1,984,254 | 2,742,081 | 3,640,368 | 791,913 | 331,546 | 277,000 | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | 1.9% | 8.4% | 38.2% | 32.8% | (78.2%) | (58.1%) | (16.5%) | (100.0%) | - | - | - | - | - |
| EBITDA (USD) | (9,134,125) | (11,129,912) | (19,928,703) | (14,520,306) | (11,480,744) | (3,394,458) | (12,112,076) | (19,190,000) | (41,762,000) | (45,754,000) | (89,083,000) | - | - | - |
| Operating Income (USD) | (10,334,826) | (12,117,223) | (20,846,517) | (15,089,796) | (12,088,290) | (4,059,221) | (13,277,770) | (23,217,000) | (46,564,000) | (53,457,000) | (97,953,000) | - | - | - |
| Operating Margin | (575.0%) | (661.7%) | (1050.6%) | (550.3%) | (332.1%) | (512.6%) | (4004.8%) | (8381.6%) | - | - | - | - | - | - |
| % EBITDA Margin | (508.2%) | (607.8%) | (1004.3%) | (529.5%) | (315.4%) | (428.6%) | (3653.2%) | (6927.8%) | - | - | - | - | - | - |
| NET Income (USD) | (10,242,757) | (12,144,984) | (20,852,023) | (15,077,052) | (12,091,280) | (4,096,562) | (13,198,387) | (23,098,000) | (45,771,000) | (52,410,000) | (96,698,000) | - | - | - |
| % Net Margin | (569.9%) | (663.2%) | (1050.9%) | (549.8%) | (332.1%) | (517.3%) | (3980.9%) | (8338.6%) | - | - | - | - | - | - |
Xspray Pharma AB - employee data
Xspray Pharma AB - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chairman of the Board of Directors | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.